STTK Shattuck Labs, Inc.
USHealthcareAs of 2026-07-10 16:00
Why STTK matters now
Shattuck Labs, Inc. (STTK) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.64 with -5.55% on the session and $318.1M in market capitalization; recent performance reads 1-month -14.51% and YTD +35.62%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-14.8M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.4%.
The latest indexable market news headline is "Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes ORBIMED ADVISORS LLC filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.80
P/S
237.12
EV/EBITDA
-3.24
DCF Value
$0.60
FCF Yield
-17.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-82.0%
Operating Margin
-5266.4%
Net Margin
-4987.4%
ROE
-60.7%
ROA
-48.8%
ROIC
-53.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-14.8M | $-0.13 |
| Q4 2025 | $0.00 | $-12.6M | $-0.12 |
| FY 2025 | $1.0M | $-48.8M | $-0.70 |
| Q3 2025 | $1.0M | $-10.1M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.75
Target (Median)
$13.00
Target Range
$7.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.09
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.